Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00311545 · SWOG Cancer Research Network · PHASE2 · withdrawn · last registry update 2013-02-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “withdrawal of support for drug supply” | – | Registry record, SWOG Cancer Research Network |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-12-24Phase 3 first posted: Janssen Research & Development, LLC, adalimumab 40 mg + sirukumab 100 mg (NCT02019472)
- 2013-05-17Phase 3 first posted: Janssen Research & Development, LLC, Sirukumab 100 mg + Sirukumab 50 mg (NCT01856309)
- 2013-02-05Results posted on the registry: SWOG Cancer Research Network, CNTO 328 (NCT00433446)
- 2013-01-28Also stopped (withdrawn): Centocor, Inc., Placebo, Velcade and dexamethasone + Siltuximab, Velcade and dexamethasone (NCT01266811)
- 2012-10-30Also stopped (withdrawn): UCB BIOSCIENCES GmbH, Olokizumab (OKZ) + Placebo (NCT01635621)
- 2012-09-21Phase 3 first posted: Janssen Pharmaceutical K.K., Sirukumab 100 mg + Sirukumab 50 mg (NCT01689532)
- 2012-05-28Phase 3 first posted: Janssen Research & Development, LLC, Placebo + Placebo (NCT01606761)
- 2012-05-23Phase 3 first posted: Janssen Research & Development, LLC, Placebo + Placebo (NCT01604343)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision